Despite the positive results regarding glycemic control, in which dulaglutide was superior to placebo and non-inferior to liraglutide, there was no significant weight loss in any group after 26 weeks
BPC-157: 0.5 mg daily (or 0.25 mg twice daily) TB-500: 2-2.5 mg twice weekly (loading phase) Duration: 4-6 weeks loading, then 2-4 weeks maintenance Maintenance TB-500: 2 mg once weekly Administration: Use separate syringes
As a result, trial protocols administer retatrutide once weekly by subcutaneous injection
RUO labeling sets the boundaries for how the page, product records, and supporting literature should be interpreted
A., Alghamdi, A., Alkhashi, T., Alkhaldi, S